Fewer than a tenth of people that would benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it releases its inaugural advice on the medications.
Given more than one billion individuals worldwide now obese, it is calling for broader and more equitable availability to these injectable treatments.
Based on forecasts, more than two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidance recognises that obesity is a lifelong illness that can be addressed with thorough and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to widespread access to the treatments that can help people shift significant body mass, explains the organization.
GLP-1 Therapy Shortage
Despite the present best projected case, the production of such drugs would only suffice for approximately 100 million people – under 10% of those who need them, per the health organization.
The recommendation encourages nations and manufacturers to increase access, via approaches like voluntary licensing.
Exclusive production rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Operate
The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and increase satiety so individuals reduce food intake.
People usually start to lose weight in the initial weeks of commencing the regular doses.
Research points to people may see weight return after a year of stopping the medication, because their typical hunger resume.
Being above a healthy weight elevates your chance for contracting diseases, including diabetes, heart disease, stroke, and some malignancies.
Obesity concerns people in every country and was linked to 3.7 million deaths worldwide in 2024, per the health agency.
